Sunshine Biopharma
SBFM
4 hedge funds and large institutions have $1.25M invested in Sunshine Biopharma in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.
326% more capital invested
Capital invested by funds: $292K → $1.25M (+$953K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
20% less funds holding
Funds holding: 5 → 4 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.33M |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$12.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$28.2K |
| 2 |
VF
Virtu Financial
New York
|
-$20K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$18.5K |
SBFM Hedge Fund Activity: Q2 2023 in Review
4 of the 6,373 institutional investors tracked by Wall St. Rank reported a position in Sunshine Biopharma (SBFM) for Q2 2023, worth a combined $1.25M — up 326% from $292K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SBFM and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.33M. The largest seller was Bank of Montreal, exiting entirely with an estimated $28.2K sold.
- 4 institutional investors held Sunshine Biopharma (SBFM) as of Q2 2023, down from 5 in Q1 2023.
- Funds reported $1.25M of Sunshine Biopharma stock for Q2 2023, up 326% quarter-over-quarter.
- 2 funds opened new Sunshine Biopharma positions in Q2 2023 and 3 closed out, a net change of -1 holder.
- The largest Sunshine Biopharma buyer in Q2 2023 was Armistice Capital, an estimated $1.33M added.
- The largest Sunshine Biopharma seller in Q2 2023 was Bank of Montreal, an estimated $28.2K sold.
Based on aggregated 13F filings for Q2 2023.